Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

NCT04116840 | Completed Phase 1 FDA Drug

• 1 other identifier: MT1002-Ⅰ-C01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

This is an open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of MT1002 for injection following intravenous bolus/infusion ascending dose administration.

Conditions

Healthy

Outcome Measures

Primary Outcomes (7)

• Maximum observed concentration (Cmax)

  Maximum observed concentration following intravenous bolus/infusion administration of MT1002 for injection

  24 hours

• Time to maximum concentration (Tmax)

  Time to maximum concentration (Tmax)

  24 hours

• Area under the concentration-time curve (AUC) from Hour 0 to the last measurable concentration (AUC0-last)

  Area under the concentration-time curve (AUC) from Hour 0 to the last measurable concentration (AUC0-last)

  24 hours

• AUC extrapolated to infinity (AUC0-∞)

  AUC extrapolated to infinity (AUC0-∞)

  24 hours

• Activated clotting time (ACT)

  Activated clotting time (ACT)

  24 hours

• Activated partial thromboplastin time (aPTT)

  Activated partial thromboplastin time (aPTT)

  24 hours

• International normalized ratio (INR)

  International normalized ratio (INR)

  24 hours

Study Arms (1)

MT1002 for Injection

EXPERIMENTAL

Single Ascending Dose following Intravenous Bolus/Infusion Administration in Healthy Subjects

Drug: MT1002 for injection

Interventions

MT1002 for injection DRUG

Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.

MT1002 for Injection

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male or female aged 18-60 years.
• Able and willing to give written informed consent.
• BMI between 18.0 and 34.0 kg/m2, inclusive.
• Subjects must be able to refrain from consuming xanthine, quinine and caffeine containing beverages, and must refrain from prolonged intensive physical exercise during the study (from 72 hours prior to dosing until the last study visit).
• Women must be:
• not pregnant
• not breast-feeding
• not planning to become pregnant during the study
• All females must have a negative serum pregnancy test at screening and a negative urine pregnancy test at check-in on Day -1. All women must agree to use an adequate method of contraception during the study and for 30 days following the end-of-study visit.
• Male subjects must agree to utilize a highly effective method of contraception (condom plus spermicide) during heterosexual intercourse from clinic admission until 30 days following the end of study visit.
• Male subjects must agree to refrain from sperm donation from clinic admission until at least 30 days following the end of study visit.

You may not qualify if:

• Any medical condition, clinical laboratory test or other reason which in the judgment of the Investigator or designee makes the subject unsuitable for the study.
• Does not tolerate venepuncture or has poor venous access that would cause difficulty for collecting blood samples.
• Has participated in an investigational drug study and received investigational drug within 30 days or 5 half-lives (whichever is longer) prior to the screening visit or who is currently participating in another clinical trial.
• Has experienced an acute illness within 14 days prior to the screening visit.
• Any clinically significant abnormalities in hematology, blood chemistry and/or urinalysis lab tests at screening or at D1.
• Known hypersensitivity to MT1002
• \. History of any drug hypersensitivity that would require urgent medical care 9. Use of aspirin or any non-steroidal anti-inflammatory drug within 14 days of Day -1 10. Any serum FSH result \<40mIU/mL 11. History, symptoms, or signs of cardiovascular or cerebrovascular disease. 12. History, symptoms, or signs of severe hepatic impairment. 13. HbA1c \>5.7% at Screening 14. History of excessive bleeding from an injury or after surgery or dental work.
• \. History of heavy or long menstrual bleeding. 16. History of blood in urine or stool or history of black stools. 17. History of easy bruising. 18. PT or aPTT \> upper limit of normal at Screening or Day -1. 19. Platelet count \< lower limit of normal at Screening or Day -1 20. History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol; a positive urine screen for drugs of abuse or breathalyzer alcohol test.
• \. Positive urinary test for drugs of abuse and/or alcohol breath test at Screening and/or at check-in on Day -1.
• \. Supine systolic blood pressure (BP) \> 130 mm Hg, diastolic BP \> 80 mm Hg, respiratory rate \>20 breaths per minute, pulse \>90 beats per minute, or temperature \>37.5º at Screening.
• \. Abnormal 12-lead ECG that may jeopardize the subject's safety to participate in this study or a screening 12-lead ECG demonstrating any one of the following: heart rate (HR) \> 100 beats per minute (bpm), QRS \> 120 milliseconds (msec), QTcF \> 450 msec, or PR \> 220 msec.
• \. Electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, or other medicinal products that lead to QT prolongation.
• \. Any clinically significant alanine aminotransferase (ALT), alkaline phosphatase (AP), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) or bilirubin abnormalities judged by the Investigator or designee at Screening.
• \. Tobacco or nicotine users except subjects who stopped using tobacco or nicotine 90 days or more before signing the informed consent.
• \. Positive Hepatitis C antibody, Hepatitis B surface antigen, or positive human immunodeficiency virus (HIV) antibody.

Sponsors & Collaborators

• Shaanxi Micot Pharmaceutical Technology Co., Ltd.: lead

Study Sites (1)

Pharmaron CPC, Inc.

Baltimore, Maryland, 21201, United States

Location

MeSH Terms

Interventions

Injections

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Mohamed Al-Ibrahim, MB

  Pharmaron CPC, Inc.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 26, 2019
• First Posted: October 7, 2019
• Study Start: April 29, 2019
• Primary Completion: August 1, 2019
• Study Completion: November 27, 2019
• Last Updated: July 29, 2022

Record last verified: 2019-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)